Teva legal chief files notice to sell 7,028 shares

TEVA’s Chief Legal Officer filed a Rule 144 notice covering potential sales of 7,028 ordinary shares tied to compensation and option activity.

Available on EDGAR 09/21/2026 - 06:40 AM EDT Accepted by SEC EDGAR 09/21/2026 - 06:40 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) received a notice under Rule 144 that Brian Savage, its Chief Legal Officer, may sell up to 7,028 ordinary shares through Citigroup Global Markets on or after September 18, 2026 on the NYSE. The shares include amounts from rollover awards and a cashless option exercise.

Key Figures

Shares covered by notice: 7,028 shares Aggregate market value: $273,062.13 Rollover shares (March 5, 2025): 550 shares +3 more

6 metrics

Shares covered by notice 7,028 shares Ordinary shares of TEVA subject to the Rule 144 Form 144 notice

Aggregate market value $273,062.13 Value listed for the 7,028 TEVA ordinary shares in the securities information section

Rollover shares (March 5, 2025) 550 shares Ordinary shares from rollover to be sold as part of the notice

Rollover shares (March 3, 2026) 1,975 shares Additional ordinary shares from rollover to be sold

Cashless option exercise shares 4,503 shares Ordinary shares from cashless option exercise and sale dated September 18, 2026

Date of notice September 18, 2026 Date on which the Rule 144 notice was filed

Key Terms

Rule 144, cashless option exercise, ordinary shares, shares from rollover, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless option exercise financial

"ORDINARY SHARES | 09/18/2026 | CASHLESS OPTION EXERCISE AND SALE"

ordinary shares financial

"ORDINARY SHARES | CITIGROUP GLOBAL MARKETS 390 GREENWICH ST"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

shares from rollover financial

"ORDINARY SHARES | 03/05/2025 | SHARES FROM ROLLOVER"

compensation financial

"09/18/2026 | COMPENSATION ORDINARY SHARES | 03/03/2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for TEVA?

The filing discloses that Brian Savage, Chief Legal Officer of TEVA, has filed a Rule 144 notice to potentially sell 7,028 ordinary shares of TEVA Pharmaceutical Industries Ltd. The planned sales are connected to compensation-related rollover shares and a cashless option exercise.

How many TEVA (TEVA) shares are covered by this Rule 144 notice?

The notice covers up to 7,028 ordinary shares of TEVA. These consist of 550 shares from a rollover dated March 5, 2025, 1,975 shares from a rollover dated March 3, 2026, and 4,503 shares from a cashless option exercise and sale dated September 18, 2026.

What is the stated value of the TEVA shares in this Form 144?

The Form 144 lists an aggregate market value of $273,062.13 for the 7,028 ordinary shares of TEVA covered by the notice. This figure appears in the securities information section related to the proposed sale through Citigroup Global Markets.

Who is the broker for the TEVA shares in this Rule 144 filing?

The broker listed is Citigroup Global Markets, located in New York. The Form 144 indicates that the 7,028 ordinary shares of TEVA are to be sold through this broker on the NYSE as part of the stated transactions.

What types of TEVA transactions are involved in the 7,028 shares?

The shares arise from three categories: shares from rollover dated March 5, 2025 (550 shares), shares from rollover dated March 3, 2026 (1,975 shares), and cashless option exercise and sale dated September 18, 2026 (4,503 shares). All are TEVA ordinary shares.

On which exchange are the TEVA shares in this Form 144 expected to be sold?

The filing indicates that the 7,028 ordinary shares of TEVA are to be sold on the NYSE. This is noted in the securities information section alongside the broker, Citigroup Global Markets, and the Rule 144 transaction details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002112339
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Savage Brian
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	CHIEF LEGAL OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	7028	273062.13	11166292643	09/18/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			550	09/18/2026	COMPENSATION
ORDINARY SHARES	03/03/2026	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			1975	09/18/2026	COMPENSATION
ORDINARY SHARES	09/18/2026	CASHLESS OPTION EXERCISE AND SALE	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			4503	09/18/2026	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED AS PART OF CASHLESS OPTION SALE AND SHARES FROM ROLLOVER SALE
Date of Notice	09/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)